Nedaplatin: a new platinum for squamous lung cancer?
Mené au Japon sur 355 patients atteints d'un carcinome épidermoïde du poumon de stade avancé ou récidivant, cet essai compare l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de nédaplatine ou de cisplatine au docétaxel en traitement de première ligne
The place of platinum doublets in first-line chemotherapy for advanced non-small-cell lung cancer in the absence of a targetable driver mutation is now well established. With the exception of pemetrexed for non-squamous non-small-cell lung cancer, no trials have shown a clear advantage for any particular third generation drug to pair with platinum, and clinicians choose from a range of equivalent drugs. By contrast, cisplatin has remained the platinum-based drug of choice in patients with a good performance status.
The Lancet Oncology , commentaire, 2014